Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qiruiweishu capsule plus rabeprazole for chronic erosive gastritis
ChiCTR2300070080Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing University of Chinese Medicine
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Qiruiweishu capsule and rabeprazole in chronic gastritis (2 arms), sponsored by The Second Affiliated Hospital of Nanjing University of Chinese Medicine. Primary endpoint: Gastroscope effect. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
Qiruiweishu capsulerabeprazole
03
Conditions
chronic gastritis
Beyond the preview
Go deeper on ChiCTR2300070080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070080.